Other
Dapagliflozin
0
Pipeline Programs↗
15
Active Trials↗
6
Companies Involved↗
Dapagliflozin is an early-stage landscape with 0 programs across 6 companies. The most active players are AstraZeneca, Jiangsu Hansoh Pharmaceutical Co., Ltd., Dong Wha Pharmaceutical Co. Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
98
clinical trials
Completed70 · 71%
Recruiting8 · 8%
Unknown status8 · 8%
Not yet recruiting5 · 5%
Terminated4 · 4%
Active, not recruiting1 · 1%
Other2 · 2%
Clinical Trials
Trial Activity
98 trials
Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
Recruiting·—·Phase 3·NCT05957887·120 enrolled
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
Recruiting·—·Phase 2·NCT05359263·222 enrolled
Dapagliflozin Plus Pioglitazone in T1DM
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT03878459·120 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)